Volumina Medical’s USD 21 million Series A success spells a new dawn for tissue regeneration.

Volumina Medical, at the forefront of MedTech innovation in Switzerland, announces a pivotal USD 21 million Series A funding milestone. This infusion of capital, sourced from both existing allies and new investors, empowers the clinical trajectory of AdipearlTM, Volumina’s flagship product designed for plastic surgery and skincare.

AdipearlTM is an injectable dermal filler, championing the regeneration of soft tissues and catering to the needs of millions undergoing reconstructive or aesthetic procedures.

Rooted in Switzerland and blossoming from the innovative ecosystem of the Swiss Federal Institute of Technology in Lausanne (EPFL). The company’s trajectory, bolstered by partnerships with companies such as BlueOcean Ventures and the European Institute of Innovation and Technology (EIT Health).

With Volumina Medical securing Series A funding, the horizon for skincare and plastic surgery advancements brightens, promising natural, durable solutions for patient wellness and aesthetic aspirations.